

There's Science – then there's **ALASTIN science.**

Purchase ALASTIN Skincare® and receive
\$50 DYSPORT®* Provider Codes Free**

**Offer terms and conditions apply. See details on back.



Dysport® (abobotulinumtoxinA) for Injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults less than 65 years of age.

*Please see Full Important Safety Information for Dysport, including Distant Spread of Toxin Effect Boxed Warning, at the end of this document.

ALASTIN Skincare® Account Level	ALASTIN Skincare® BUY-IN	ALASTIN Skincare® Receive for FREE	DYSPORT® Receive for FREE # of \$50 Dysport® Provider Codes
PRACTICE BUILDER	\$5,000 Products of your choice	\$600 in free goods products of your choice	12
ADVANTAGE BRONZE	\$5,000 Products of your choice	24% back on order in free goods products for your choice	16
ADVANTAGE SILVER	\$5,000 Products of your choice	28% back on order in free goods products for your choice	20
ADVANTAGE GOLD	\$5,000 Products of your choice	32% back on order in free goods products for your choice	24
ADVANTAGE PLATINUM	\$5,000 Products of your choice	40% back on order in free goods products for your choice	28

Galderma Dysport® & Alastin Q2 2023 Promotion Offer Sheet Terms and Conditions

- “Qualifying HCPs” are certain healthcare professional accounts who are members of both the Alastin Skincare loyalty programs and the ASPIRE Galderma Practice Rewards loyalty programs as of April 10, 2023.
- “Qualifying Purchase” is a purchase of \$5,000 or more of Alastin Products by a Qualifying HCP on a single order placed between April 10, 2023 through April 28, 2023 (“Offer Period”) and delivered via a single shipment.

For each Qualifying Purchase, Qualifying HCP shall receive the following number of \$50 Dysport Provider Codes based on its Alastin Account level as of April 10, 2023:

Alastin Account Level as of April 10, 2023	Number of \$50 Dysport Provider Codes Awarded
Practice Builder Accounts	12
Advantage Bronze Level	16
Advantage Silver Level	20
Advantage Gold Level	24
Advantage Platinum Level	28

- Galderma shall provide any Dysport Provider Codes to a Qualifying HCP via www.aspirepracticerewards.com within five (5) business days after verification by both Galderma and Alastin that all offer criteria has been met.
- All Qualifying Purchases must be placed through Alastin.
- Qualifying HCPs can make multiple Qualifying Purchases during the Offer Period. However, this offer is limited to 240 Dysport Provider Codes per Qualifying HCP.
- Qualifying HCPs may use Provider Codes only for adult patients who receive a Dysport treatment in accordance with the product’s FDA-approved indication and labeling. If providers have questions about these additional Galderma Terms and Conditions, please call 1-844-5ASPIRE.
- Qualifying patients must be members of the ASPIRE Galderma Rewards Loyalty Program.
- Provider Codes shall expire sixty (60) days from issuance to an HCP.
- Offer cannot be combined with any other offer or promotion.
- Offer valid only in the U.S., excluding territories, and void where prohibited, taxed or otherwise restricted by law.
- Galderma and Alastin each reserve the right to cancel or modify this offer without notice.
- Patients are eligible for this offer only if they pay for their entire treatment themselves and if no part of their treatment is covered by insurance or any other third-party payor. This offer excludes any treatment using a Galderma product that is reimbursed by Medicaid, Medicare, or any other federal or state benefit programs, including state medical assistance programs. Patients are not eligible for this offer if their private insurance, HMO, or any other health benefit program pays for all or part of their treatment. If any form of reimbursement is sought from a third-party, patients may be required to disclose the value of the Provider Code to that party. This offer is not available to patients who are Galderma employees or their spouses.
- All Provider Codes must be submitted by the treating provider via www.aspirepracticerewards.com. Galderma will reimburse the provider for the face value of used provider codes, provided that the healthcare provider has complied with these terms and conditions. Individual Provider Codes are valid for one-time use. his offer is limited to one (1) Provider Code per patient. Promotion Provider Codes cannot be combined with any other offer or promotion. Provider Codes have no cash value without simultaneous purchase of a Dysport treatment, and are void if sold, transferred or exchanged. Provider Codes are valid only in the U.S. and Puerto Rico, excluding all other territories, and void where prohibited, taxed or otherwise restricted by law.
- Providers acknowledge that any discount or rebate provided hereunder is commensurate with the fair market value of the products. No discount or rebate provided hereunder is intended to be, nor shall it be construed as, an offer or payment made, whether directly or indirectly, to induce the referral of patients; the purchase, lease or order of any item or service from Galderma; or the recommending or arranging for the purchase, lease or order of any item or service from Galderma.
- By participating in this offer, providers agree to all of the terms and conditions of this offer. Galderma assumes no responsibility for lost, late, incomplete, or incorrect submissions that fail to be properly entered and submitted to www.aspirepracticerewards.com for any reason. Provider Codes will be processed and reimbursed in U.S. dollars only.

Dysport® (abobotulinumtoxinA) for Injection is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults <65 years of age.

Important Safety Information Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of *Dysport* and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

CONTRAINDICATIONS

- Hypersensitivity to any botulinum toxin product or excipients
- Allergy to cow’s milk protein
- Infection at the proposed injection site(s)

WARNINGS AND PRECAUTIONS

- The potency Units of *Dysport* are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of *Dysport* cannot be compared to or converted into units of any other botulinum toxin products.
- Immediate medical attention may be required in cases of respiratory, speech or swallowing difficulties, or serious hypersensitivity reactions.
- Recommended dose and frequency of administration should not be exceeded.
- Dry eye may occur with glabellar line treatment, if symptoms persist, consider referring patient to an ophthalmologist.
- Concomitant neuromuscular disorder may exacerbate clinical effects of treatment.

ADVERSE REACTIONS

- In clinical studies, the most frequently reported adverse events (≥2%) were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, nausea, and blood present in urine.

DRUG INTERACTIONS

- Concomitant use of *Dysport* and aminoglycosides or other agents interfering with neuromuscular transmission or muscle relaxants, should be observed closely because effect of *Dysport* may be potent
- Anticholinergic drugs may potentiate systemic anticholinergic effects.
- The effect of administering different botulinum neurotoxins during course of treatment with *Dysport* is unknown.

USE IN SPECIFIC POPULATIONS

- *Dysport* is not recommended for use in children or pregnant women.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see *Dysport* Full Prescribing Information including Medication Guide at DysportUSA.com

GALDERMA
EST. 1981